SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

TGTXs breakout to a fresh 52-week high is drawing attention as traders focus on the upcoming Q3 report and BRIUMVIs sales ramp. Buyout speculation and possible short covering are also part of the bullish discussion, but a deal remains unconfirmed, and some traders attribute the move to the companys commercial growth instead.

CorMedix, Inc. is a pharmaceutical and medical device company, which engages in the development and commercialization of therapeutic products for the prevention and treatment of diseases and conditions. The company was founded by Antony E. Pfaffle on July 28, 2006 and is headquartered in Berkeley Heights, NJ.

CorMedix Inc

DaVitas warning that DefenCath reimbursement could decline sharply as quarterly Medicare rates reset has fueled concern about pricing and future revenue, alongside a steep selloff. Traders disagree over whether the warning signals lasting pressure or is a preliminary estimate that overstates the risk to adoption and sales.

The Clorox Co. engages in the manufacture and marketing of consumer and professional products. It operates through the following business segments: Health and Wellness, Household, Lifestyle, and International. The Health and Wellness segment consists of cleaning products, professional products and vitamins, minerals and supplements mainly marketed and sold in the United States. The Household segments consists of bags and wraps, grilling products and cat litter marketed and sold in the United States. The Lifestyle segment refers to food, natural personal care products and water-filtration products marketed and sold in the United States. The International segment covers products sold outside the United States, excluding natural personal care products. The company was founded by Edward Hughes, Charles Husband, William Hussey, Rufus Myers, and Archibald Taft on May 3, 1913 and is headquartered in Oakland, CA.

Clorox Co.

Clorox is drawing attention after a steep selloff, with traders weighing its upcoming earnings and new CEO appointment against concerns about weak growth, margin pressure, and dividend sustainability. Some view the beaten-down shares and high yield as a value opportunity, while others remain cautious about the turnaround and further downside.

The Walt Disney Co. engages in the business of international family entertainment and media enterprise. It owns and operates television and radio production, distribution and broadcasting stations, direct-to-consumer services, amusement parks, and hotels. It operates through the following business segments: Disney Entertainment, ESPN, and Disney Parks, Experiences, and Products. The company was founded by Walter Elias Disney on October 16, 1923 and is headquartered in Burbank, CA.

Walt Disney Co (The)

Walt Disney Co

A stronger-than-expected quarter, with parks and streaming cited as bright spots, has renewed bullish interest in Disney and fueled discussion of a possible technical breakout. Skeptics point to the stocks long-running lack of appreciation and resistance near recent levels.

Costco Wholesale Corp. engages in the provision of operation of membership warehouses through wholly owned subsidiaries. It operates through the following geographical segments: United States, Canada, and Other International Operations. The company was founded by James D. Sinegal and Jeffrey H. Brotman in 1983 and is headquartered in Issaquah, WA.

Costco Wholesale Corp

Costco is drawing attention for renewed strength around the $1,000 level as traders rotate toward defensive retailers amid weakness in tech; bulls cite strong digital sales and membership retention and upbeat analyst views, while skeptics point to its premium valuation and slowing membership growth.

Energy Transfer LP engages in natural gas pipeline transportation and transmission services. It operates through the following segments: Intrastate Transportation and Storage, Interstate Transportation and Storage, Midstream, NGL and Refined Products Transportation and Services, Crude Oil Transportation and Services, Investment in Sunoco LP, Investment in USAC, and All Other. The Intrastate Transportation and Storage segment owns and operates natural gas transportation pipelines. The Interstate Transportation and Storage segment includes transportation pipelines, storage facilities, and gathering systems and delivery of natural gas to industrial end-users and other pipelines. The Midstream segment consists of natural gas gathering, compression, treating, processing, storage, and transportation. The NGL and Refined Products Transportation segment engages in the operations transport, store and execute acquisition, and marketing activities utilizing a complementary network of pipelines, storage and blending facilities, and strategic off-take locations that provide access to multiple NGL markets. The Crude Oil Transportation and Services segment provides transportation, terminalling, acquisition, and marketing services to crude oil markets. The Investment in Sunoco LP segment refers to the distribution of motor fuels to independent dealers, distributors, and other commercial customers and the distribution of motor fuels to end-user customers at retail sites. The Investment in USAC segment offers compression services to its customers in connection with infrastructure applications including both allowing for the processing and transportation of natural gas through the domestic pipeline system and enhancing crude oil production through artificial lift processes. The company was founded by Kelcy L. Warren in 1996 and is headquartered in Dallas, TX.

Energy Transfer LP - Unit

Energy Transfer LP Unit

A strong quarterly report and improved full-year outlook are driving attention, alongside managements comments about advanced talks to serve data centers and other large power customers with natural-gas infrastructure. Traders see growth potential and value in the distribution, while many are frustrated by the muted unit-price reaction.

Strive, Inc. engages in the provision of an asset management Bitcoin treasury. It is focused on maximizing value for shareholders, accumulating bitcoin and outperforming bitcoin over the long run. The company was founded by Arshia Sarkhani, Jackson Fairbanks, Arman Sarkhani, and Kyle Fairbanks on March 9, 2022 and is headquartered in Dallas, TX.

Strive Inc. - Ordinary Shares - Class A

Strive Inc.

ASST is drawing attention amid a sharp selloff in Bitcoin-linked stocks, with traders pointing to crypto-market weakness and liquidation fears. The debate centers on whether its Bitcoin-treasury exposure amplifies the downturn, while concerns about preferred-stock financing and dilution weigh against dip-buying calls from bulls.

Carvana Co. is a holding company and an eCommerce platform, which engages in the buying and selling of used cars. The company was founded by Ernest Garcia, III, Benjamin Huston and Ryan Keeton in 2012 and is headquartered in Tempe, AZ.

Carvana Co. - Ordinary Shares - Class A

Carvana Co.

Carvanas Q3 report, record revenue and unit sales, and the SECs decision to close its investigation without recommending enforcement action fueled a sharp rally and renewed short-squeeze speculation. Traders remain divided: bulls focus on growth and the potential for further covering, while bears point to an EPS miss, shrinking margins, and the end of numerical guidance as reasons to doubt the move.

Hyperliquid Strategies, Inc. is a holding and operating company, which engages in the business of crypto asset management. The firm operates as a digital asset treasury company which focuses on the Hyperliquid ecosystem. The company was founded on July 2, 2025 and is headquartered in New York, NY.

Hyperliquid Strategies Inc.

PURR is drawing attention as a public-market proxy for Hyperliquids HYPE token, with traders watching HYPEs moves and debating why PURR often fails to keep pace. Bulls point to growing HYPE holdings and ecosystem potential, while bears focus on share issuance through the companys equity facility and the resulting dilution risk.

The Coca-Cola Co. engages in the manufacturing and marketing of non-alcoholic beverages. It operates through the following segments: Europe, Middle East and Africa, Latin America, North America, Asia Pacific, Global Ventures, and Bottling Investments. The company was founded by Asa Griggs Candler on May 8, 1886 and is headquartered in Atlanta, GA.

Coca-Cola Co

Coca-Colas Q3 earnings beat and raised full-year outlook are driving attention, with traders pointing to stronger global volume growth and share gains. The reaction is tempered by flat North American volume, questions about shipment timing and consumer price sensitivity, and concerns that the stocks valuation is stretched.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Vanda Pharmaceuticals (VNDA) Reports Q3 Loss, Tops Revenue Estimates

Vanda (VNDA) delivered earnings and revenue surprises of +48.61% and +5.99%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?

Vanda Pharmaceuticals Reports Third Quarter 2026 Financial Results

Vanda Pharmaceuticals Reports Third Quarter 2026 Financial Results Vanda Pharmaceuticals Reports Third Quarter 2026 Financial ResultsPR NewswireWASHINGTON, Oct. 28, 2026 Q3 2026 Total Revenues increased 24% to $69.8 million compared to Q3 2025 and 38% compared to Q2 2026Q3 2026 Total Operating...

Vanda Pharmaceuticals Targets Major GLP-1 Market Challenge with Positive Trial Outcomes

Vanda Pharmaceuticals reports positive Phase 3 results for Nereus, demonstrating reduced vomiting linked to GLP-1 receptor agonist therapy.read more...

Vanda Pharmaceuticals Announces Positive Results from Study 3601 of NEREUS (tradipitant) for Prevention of GLP-1-Induced Vomiting

Vanda Pharmaceuticals Announces Positive Results from Study 3601 of NEREUS (tradipitant) for Prevention of GLP-1-Induced Vomiting Vanda Pharmaceuticals Announces Positive Results from Study 3601 of NEREUS (tradipitant) for Prevention of GLP-1-Induced VomitingPR NewswireWASHINGTON, Oct. 27, 2026...

Fortrea Holdings Inc. (FTRE) Earnings Expected to Grow: Should You Buy?

Fortrea Holdings Inc. (FTRE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Vanda Pharmaceuticals to Announce Third Quarter 2026 Financial Results on October 28, 2026

Vanda Pharmaceuticals to Announce Third Quarter 2026 Financial Results on October 28, 2026 Vanda Pharmaceuticals to Announce Third Quarter 2026 Financial Results on October 28, 2026PR NewswireWASHINGTON, Oct. 21, 2026 Conference Call and Webcast to FollowWASHINGTON, Oct. 21, 2026 /PRNewswire...

XENE's Depression Trial Setback: Is Its Pipeline Still Attractive?

Xenon pauses enrollment in late-stage depression trials after unexpected side effects, while its epilepsy pipeline offers growth potential.

Vanda Pharmaceuticals Provides Update on VQW-765 Clinical Development Program

Vanda Pharmaceuticals Provides Update on VQW-765 Clinical Development Program Vanda Pharmaceuticals Provides Update on VQW-765 Clinical Development ProgramPR NewswireWASHINGTON, Oct. 14, 2026Phase III clinical study of VQW-765 in adults with social anxiety disorder did not meet its primary...

Vanda Pharmaceuticals Announces Presentation at 2026 EADV Annual Meeting

Vanda Pharmaceuticals Announces Presentation at 2026 EADV Annual Meeting Vanda Pharmaceuticals Announces Presentation at 2026 EADV Annual MeetingPR NewswireWASHINGTON, Oct. 2, 2026WASHINGTON, Oct. 2, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Nasdaq: VNDA) today announced participation at the...

VNDA Stock Fades After Hetlioz Sleep-Trial Win — Here’s Why

Equity

Vanda said a late-stage study of Hetlioz (tasimelteon), already sold for two rare body-clock disorders, met its main goal in delayed sleep-wake phase disorder (DSWPD).

$VNDA Q3 &#39;26 Earnings Results &amp; Recap

• Reported GAAP EPS of -$0.37 up 2.63% YoY
• Reported revenue of $1.61M down -97.14% YoY
• Vanda Pharmaceuticals expects full-year 2026 total revenue of greater than $240M; no quantified margin or earnings guidance was provided for full-year 2026 in the financial update.

Stocktwits

Vanda Pharmaceuticals Inc

 Q3 '26 Earnings Results & Recap

• Reported GAAP EPS of -$0.37 up 2.63% YoY
• Reported revenue of $1.61M down -97.14% YoY
• Vanda Pharmaceuticals expects full-year 2026 total revenue of greater than $240M; no quantified margin or earnings guidance was provided for full-year 2026 in the financial update.

This account has been verified as an official STOCKTWITS representative.

Verified Account

Stocktwits Earnings

• Reported GAAP EPS of -$0.37 up 2.63% YoY
• Reported revenue of $1.61M down -97.14% YoY
• Vanda Pharmaceuticals expects full-year 2026 total revenue of greater than $240M; no quantified margin or earnings guidance was provided for full-year 2026 in the financial update.

Vanda Pharmaceuticals reported higher year-to-date net losses, cash decreased by $123.4M from December 31, 2025, and pending FDA-related court challenges involving HETLIOZ insomnia and NEREUS gastroparesis.

Vanda Pharmaceuticals reported Fanapt sales and prescription growth, positive Phase III results for NEREUS in GLP-1-associated vomiting, and BYSANTI approval with launch expected in Q4 2026.

Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The firm intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, NEREUS, Ponvory, and HETLIOZAccess. The company was founded by Mihael Hristos Polymeropoulos and Argeris N. Karabelas in 2002 and is headquartered in Washington, DC.

Extremely Bullish Sentiment

<ul class="summary-bullets"><li>In the trial, patients took 20 mg once daily for 28 days; treated patients fell asleep 42.5 minutes earlier versus 5.4 minutes on placebo — a 37-minute gap.</li><li>The “pivotal” trial analyzed just 20 patients per arm after screening more than 260 people over five years.</li><li>Investors also remember the FDA twice rejected Hetlioz for jet lag, citing how the studies were designed.</li></ul>Shares of Vanda Pharmaceuticals (<a class="mention" data-mention="$VNDA" data-symbol-id="VNDA" href="https://stocktwits.com/symbol/VNDA" target="_blank">VNDA</a>) opened 3% higher on Wednesday after a late Tuesday readout in delayed sleep-wake phase disorder, to eventually give up all gains as investors focused on the small trial population and generic competition to the drug.The stock was down 1% at the time of writing, despite a two-digit after-hours surge on Tuesday. &nbsp;<h2 class="st-heading-2">What The <a class="mention" data-mention="$VNDA" data-symbol-id="VNDA" href="https://stocktwits.com/symbol/VNDA" target="_blank">VNDA</a> Trial Showed</h2>Vanda said a late-stage study of Hetlioz (tasimelteon), already sold for two rare body-clock disorders, met its main goal in delayed sleep-wake phase disorder (DSWPD). In DSWPD, the internal clock is locked late: people cannot fall asleep at a normal hour and struggle to wake for work or school. The company estimates that 0.5 million to 4.1 million U.S. adults may be affected.In the trial, patients took 20 mg once daily for 28 days. Treated patients fell asleep 42.5 minutes earlier versus 5.4 minutes on placebo — a 37-minute gap. Sixty percent of the drug group advanced sleep by at least 30 minutes, versus 15% on placebo. Safety matched the existing label. Vanda plans to discuss the data with the U.S. Food and Drug Administration and file for a new use. If approved, Hetlioz would be the first medicine specifically cleared for DSWPD.<h2 class="st-heading-2">Why The Stock Did Not Rally</h2>The “pivotal” trial analyzed just 20 patients per arm after screening more than 260 people over five years. The main measure was a diary, not an objective sleep tracker. Investors also remember the FDA twice rejected Hetlioz for jet lag, citing how the studies were designed.Further, generic versions have already slashed Hetlioz sales — down 66% year over year to $5.6 million in the latest reported quarter. A new label on a product already facing cheap copies may add little revenue. Vanda is also burning cash while Fanapt, its approved drug for schizophrenia and acute manic or mixed episodes of bipolar I disorder, grows, and other pipeline bets remain unproven.Vanda is also awaiting an FDA decision on Quimilza in the treatment of generalized pustular psoriasis. The FDA is slated to decide on the drug by December 12.<h2 class="st-heading-2">How Did <a class="mention" data-mention="$VNDA" data-symbol-id="VNDA" href="https://stocktwits.com/symbol/VNDA" target="_blank">VNDA</a> Retail Traders React?</h2>On Stocktwits, retail sentiment around <a class="mention" data-mention="$VNDA" data-symbol-id="VNDA" href="https://stocktwits.com/symbol/VNDA" target="_blank">VNDA</a> stock rose from bearish to extremely bullish territory over the past 24 hours, while message volume rose from normal to extremely high levels.A Stocktwits user highlighted that the company is currently unprofitable. The stock is doomed until it can turn a profit again, they said.<stembedurl>https://stocktwits.com/Ctres06/message/665434676</stembedurl>Another user highlighted the small nature of the study, which they said will not suffice for FDA approval.<stembedurl>https://stocktwits.com/Massimo21/message/665425060</stembedurl><a href="https://stocktwits.com/symbol/VNDA">VNDA stock</a> has fallen 43% year-to-date.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/ai-labs-in-focus-us-ftc-reportedly-opens-probe-into-open-ai-anthropic-following-surge-in-rogue-ai-agents/cZMFhPuRBL7">AI Labs In Focus: US FTC Reportedly Opens Probe Into OpenAI, Anthropic Following Surge In Rogue AI Agents</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Representative image: Colorful pills in glass bottles. Courtesy: Getty Images

Vanguard Total Stock Market ETF

SPDR S&P Biotech ETF

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$3.79
Prev Close	$4.05
Open	$4.03
Dividend Yield	0.00%
50-Day Moving Average	$4.79
Beta	0.81
Avg. Volume	977,851.40
PE Ratio	-0.82

52-Week High	$9.94
52-Week Low	$3.74
Market Capitalization	$244.87M
EPS (Annual)	-$3.74
Price to Book	1.15
Revenue Per Employee	$405,450.28

Feed

News

Sentiment

Earnings

Fundamentals

Info

VNDA Fundamentals